NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the ORAL Sync Phase 3 study (A3921046) of tofacitinib (development code: CP-690,550), formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis (RA), met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical funct

THOUSAND OAKS, Calif., & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--World-class professional golfer and psoriatic arthritis patient Phil Mickelson today launches “On Course with Phil,” a disease education program for people with certain chronic inflammatory joint and skin conditions, in partnership with Amgen (NASDAQ: AMGN) and Pfizer, Inc. (NYSE:PFE). This program seeks to inspire patients with psoriatic arthritis, rheumatoid arthritis or plaque psoriasis to take action, educate themselves and work wi

BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (the “Company”), a wholly owned subsidiary of Pfizer Inc., announced today the final results of its tender offer to purchase (the “Fundamental Change Put Option”) any and all of its outstanding 1 1/4% Convertible Senior Notes Due 2026 (the “Securities”). The Fundamental Change Put Option expired on February 28, 2011, at 11:59 p.m., New York City time (the “Expiration Date”). The Paying Agent has advised the Company that prior to the Exp

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has combined operations with King Pharmaceuticals, Inc. On February 28, 2011, Pfizer completed its acquisition of King through the merger of its wholly owned subsidiary, Parker Tennessee Corp., with and into King. King is now a wholly owned subsidiary of Pfizer. Under the terms of the transaction, each outstanding share of King common stock has been converted into the right to receive $14.25, net in cash (without interest

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today provided an update to its development pipeline, available at www.pfizer.com/pipeline. The updated pipeline includes an overview of the company’s research and a list of compounds in development with targeted indication, phase of development and, for late-stage programs, mechanism of action. The company has redesigned the format of the development pipeline, providing interactive capabilities that will allow interested parties to search for assets by dev

NEW YORK & MALVERN, Pa.--(BUSINESS WIRE)--XIAPEX® (collagenase clostridium histolyticum), a new non-surgical treatment option for Dupuytren’s contracture in adult patients with a palpable cord, has been granted marketing authorization by the European Commission and is expected to be available for use in some European markets later this year.1 Collagenase clostridium histolyticum is the first injectable treatment to be approved in the EU for the treatment of Dupuytren's contracture. Pfizer (NYSE:

CONCORD, N.H.--(BUSINESS WIRE)--NH Citizens Health Initiative, in collaboration with Pfizer, Inc. and the New Hampshire Medical Society, is premiering two mini-documentaries detailing what it means to be a patient and a provider in a patient-centered medical home. The videos were created by The Initiative and Pfizer in an effort to describe the value and benefits of medical homes. Patient-centered medical homes put a patient’s needs at the fore and provide primary, preventive, and chronic condit

WASHINGTON--(BUSINESS WIRE)--Today, in a 6-2 decision, the U.S. Supreme Court affirmed the ruling of the U.S. Court of Appeals for the Third Circuit in favor of Pfizer’s subsidiary Wyeth, in Bruesewitz v. Wyeth. The Third Circuit determined that the National Childhood Vaccine Injury Act prevents civil suits against manufacturers of FDA-approved childhood vaccines based on a claim that a particular vaccine should have been designed differently. “Vaccines are one of modern medicine's greatest succ

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY - News) and Pfizer Inc. (NYSE:PFE - News) today announced the publication of the full results of the AVERROES study of apixaban in The New England Journal of Medicine. Conducted in 36 countries, the study was coordinated by the Population Health Research Institute (PHRI) at McMaster University and at Hamilton Health Sciences in Canada. The study demonstrated that, for patients with atrial fibrillation (AF) who we

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has entered into a definitive agreement to purchase Ferrosan’s consumer healthcare business, which includes dietary supplements and lifestyle products, from Altor 2003 Fund GP Limited. Based in Copenhagen, Ferrosan is an innovative and long-established consumer healthcare company in the Nordic region with a portfolio of leading brands. Since 1920, Ferrosan has grown to serve a broader market including Russia, the Ukraine,